Dimensional Fund Advisors LP Assembly Biosciences, Inc. Transaction History

Dimensional Fund Advisors LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.8 - $1.74 $30,802 - $66,995	-38,503 Reduced 11.93%	284,185 $238,000
Q4 2022 Feb 09, 2023	SELL	$1.09 - $20.4 $8,143 - $152,408	-7,471 Reduced 2.26%	322,688 $419,000
Q3 2022 Nov 10, 2022	SELL	$1.7 - $20.52 $42,109 - $508,280	-24,770 Reduced 6.98%	330,159 $542,000
Q2 2022 Aug 12, 2022	SELL	$1.35 - $2.29 $35,276 - $59,839	-26,131 Reduced 6.86%	354,929 $745,000
Q1 2022 May 13, 2022	SELL	$1.46 - $2.45 $251,657 - $422,301	-172,368 Reduced 31.15%	381,060 $785,000
Q4 2021 Feb 09, 2022	BUY	$2.13 - $3.46 $413,460 - $671,630	194,113 Added 54.02%	553,428 $1.29 Million
Q3 2021 Nov 12, 2021	SELL	$3.14 - $3.9 $345,016 - $428,524	-109,878 Reduced 23.42%	359,315 $1.25 Million
Q2 2021 Aug 12, 2021	SELL	$3.8 - $4.56 $107,912 - $129,494	-28,398 Reduced 5.71%	469,193 $1.82 Million
Q1 2021 May 14, 2021	SELL	$4.33 - $6.63 $66,435 - $101,724	-15,343 Reduced 2.99%	497,591 $2.29 Million
Q4 2020 Feb 25, 2021	BUY	$4.87 - $17.29 $2.5 Million - $8.87 Million	512,934 New	512,934 $3.1 Million

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $714M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Dimensional Fund Advisors LP with notifications on news.